Reelin Therapeutics, Inc.

Reelin Therapeutics, Inc. is a San Diego-based small business focused on biomedical research and therapeutic development, specializing in innovative approaches to treating neurodegenerative and inflammatory diseases. Registered in SAM.gov since January 2019, the company operates as a for-profit corporate entity with a dedicated Research and Development Division that pursues advanced medical research targeting complex health challenges. The organization's primary focus appears to be developing novel therapeutic interventions using advanced molecular and immunological techniques, with a particular emphasis on modulating protein interactions and inflammatory processes.

The company has secured multiple federal grant awards from prominent health research agencies, including the National Institute on Aging and the National Institute of Arthritis and Musculoskeletal and Skin Diseases. These project grants, ranging from $258,213 to unspecified amounts, support research into critical areas such as Alzheimer's disease, Down syndrome, and rheumatoid arthritis. Specifically, Reelin Therapeutics has conducted research on developing next-generation gamma-secretase modulators for Alzheimer's treatment, investigating the role of Reelin protein in inflammatory processes, and exploring anti-Reelin monoclonal antibodies as potential therapeutic interventions. Their research methodologies involve comprehensive approaches including medicinal chemistry, in vitro and in vivo optimization, preclinical studies, and the development of targeted antibody therapies aimed at systematically downregulating inflammation-driven molecular processes across various disease contexts.